Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 73 of 97, showing 5 Applications out of 482 total, starting on record 361, ending on 365

# Protocol No Study Title Investigator(s) & Site(s)

361.

ECCT/16/05/02   Monitoring Pre-exposure Prophylaxis for Young Adult women (MPYA)
    Next generation real-time monitoring for PrEP adherence in young Kenyan women   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
1. Thika Partners Study Clinic (Partners in Health Research and Development) (Kiambu county)
2. Partners in Prevention, Kisumu Site (Kisumu county)
 
View

362.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View

363.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

364.

ECCT/16/03/02   Infant TB Infection Prevention Study (“iTIPS”)
    Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants       
Principal Investigator(s)
1. Grace John-Stewart
Site(s) in Kenya
1. Kisumu East District Hospital (Kisumu county)
2. Ahero County Hospital (Kisumu county)
3. Bondo sub-County Hospital (Kisumu county)
 
View

365.

ECCT/16/02/06   A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults.
    A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP]   
Principal Investigator(s)
1. Christina Wesonga Obiero
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme
 
View